medwireNews: The 6-year results from the CLL14 study confirm the long-term benefits of a 1-year regimen of venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukemia (CLL) and co-existing conditions.
14-06-2023 | Chronic Lymphocytic Leukemia | News
EHA 2023